TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24373610
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Aspirin and Fish Oil for 7 days
Study: 22435509
Drug: Sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential therapy (lansoprazole, amoxicillin, clarithromycin, and metronidazole)
Study: 22435509
Drug: Concomitant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant therapy (lansoprazole, amoxicillin, clarithromycin, and metronidazole)
Study: 10754950
Drug: 1% benzalkonium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% benzalkonium chloride vaginal suppository and neonatal bath
Study: 10754950
Drug: Placebo vaginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo vaginal suppository and neonatal bath
Study: 8965890
Drug: Pamidronate (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate (90 mg, two-hour intravenous infusion monthly for 12 cycles)
Study: 1582586
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of ethanolamine oleate and thrombin
Study: 31537221
Drug: Bronchoscope treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bronchoscope treatment
Study: 30064517
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) bolus of tranexamic acid (TXA) peri-operatively plus oral TXA post-operatively for 24 hours
Study: 30064517
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) bolus of TXA peri-operatively
Study: 26329313
Drug: Propofol-ketamine combination
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol-ketamine combination (GroupPK, n: 48)
Study: 19535988
Drug: 0.15 mg
Normalized name: iodine 0.15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15 mg kg(‐1) ketamine followed by a continuous infusion of 1.4 microg kg(‐1) min(‐1) over 24 h
Study: 19535988
Drug: 0.15 mg
Normalized name: iodine 0.15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15 mg kg(‐1) ketamine
Study: 17591127
Drug: Midazolam sedation
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam sedation (intravenous)
Study: 10343981
Drug: Immunosuppressive agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunosuppressive agents (cyclosporin A and methotrexate)
Study: 10343981
Drug: Choleretic agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Choleretic agents (ursodeoxycholic acid)
Study: 10343981
Drug: Cupruretic agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cupruretic agents
Study: 7769297
Drug: Licensed subvirion
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Licensed subvirion vaccine
Study: 1707337
Drug: Cronassial (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cronassial (100 mg) administered by intramuscular (IM) injection daily
Study: 1707337
Drug: Vincristine (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vincristine (2.0 mg/m2 every other week by bolus injection followed by a 3-day continuous IV infusion)
Study: 1707337
Drug: Dexamethasone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (50 mg/d for 3 days weekly or every other week)
Study: 6805176
Drug: 0.25 ml
Normalized name: mineral oil 0.25 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 ml polycomponent meningococcal vaccine
Study: 6805176
Drug: 0.5 ml
Normalized name: ethanol 0.5 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 ml polycomponent meningococcal vaccine
Study: 6805176
Drug: 1.0 ml
Normalized name: digoxin 0.25 mg in 1.0 mL INTRAVENOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 ml polycomponent meningococcal vaccine
Study: 6805176
Drug: Placebo (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.5 ml physiological saline)
Study: 30951604
Drug: Person-centered physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Person-centered physical therapy prehabilitation program
Study: 26946925
Drug: Antibiotic-impregnated catheters
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antibiotic-impregnated catheters
Study: 26946925
Drug: Heparin-impregnated catheters
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-impregnated catheters
Study: 16282291
Drug: Azithromycin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (250 mg/day)
Study: 12113567
Drug: Silicone intraocular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silicone intraocular lens (Sl‐‐30NB) with concurrent ocular diseases
Study: 12113567
Drug: Silicone intraocular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silicone intraocular lens (Sl‐‐30NB) without concurrent ocular diseases
Study: 12113567
Drug: Acrylic intraocular
Normalized name: acrylate
DrugBank: Acrylic Acid (DB02579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acrylic intraocular lens (Acrysof MA60BM) with concurrent ocular diseases
Study: 12113567
Drug: Acrylic intraocular
Normalized name: acrylate
DrugBank: Acrylic Acid (DB02579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acrylic intraocular lens (Acrysof MA60BM) without concurrent ocular diseases
Study: 8525537
Drug: Intravenous ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ganciclovir (6 mg/kg once a day, Monday through Friday) for 4 or more weeks
Study: 28859326
Drug: COBRA therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: COBRA therapy (prednisolone, MTX and SSZ)
Study: 28859326
Drug: COBRA-light and
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: COBRA-light and COBRA therapy
Study: 25588594
Drug: Ropivacaine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine plus 0.5 µg.kg‐1 dexmedetomidine (group LD1)
Study: 25588594
Drug: Ropivacaine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine plus 1 µg.kg‐1 dexmedetomidine (group LD2)
Study: 25588594
Drug: Retrobulbar ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retrobulbar ropivacaine (group L)
Study: 17328583
Drug: AZSR (extended-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZSR (extended-release microsphere formulation of azithromycin)
Study: 17328583
Drug: AZSR with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZSR with antacid
Study: 7524607
Drug: Mitozantrone (7-14
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitozantrone (7-14 mg m-2), Methotrexate (35 mg m-2, max 50 mg), Mitomycin (7 mg m-2) with filgrastim (5 micrograms kg-1)
Study: 7524607
Drug: Mitozantrone (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitozantrone (7 mg m-2)
Study: 7524607
Drug: Mitozantrone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitozantrone (10 mg m-2)
Study: 7524607
Drug: Mitozantrone (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitozantrone (12 mg m-2)
Study: 7524607
Drug: Mitozantrone (14
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitozantrone (14 mg m-2)
Study: 2884788
Drug: H1-antihistamine preparation
Normalized name: Ahist Antihistamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: H1-antihistamine preparation terfenadine
Study: 2884788
Drug: Combined administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined administration of H1-antihistamine terfenadine and H2-antihistamine ranidine
Study: 2884788
Drug: H2-antihistamine preparation
Normalized name: Ahist Antihistamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: H2-antihistamine preparation ranidine
Study: 24928191
Drug: Spray and
Normalized name: Spray and Stretch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spray and stretch
Study: 19914598
Drug: Alcohol at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol at .25 g/kg
Study: 19914598
Drug: Alcohol at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol at .5 g/kg
Study: 19914598
Drug: Alcohol at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol at .75 g/kg
Study: 18655556
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy with hypha cordyceps (0.33 g per capsule, 3 capsules per day) and ginkgo leaf tablet (0.23 g per tablet, 1 tablet per day) for 3 months
Study: 16192842
Drug: Rapid titration
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid titration group (RTG) - Quetiapine 200 mg/day on day 1; 400 mg/day on day 2; 600 mg/day on day 3
Study: 16192842
Drug: Conventional titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional titration group (CTG) - Quetiapine 50 mg/day on day 1; 100 mg/day on day 2; 200 mg/day on day 3; 300 mg/day on day 4; 400 mg/day on day 5
Study: 11875640
Drug: Alcohol (females
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (females 0.35 g/kg; males 0.45 g/kg)
Study: 1793726
Drug: Zeniplatin at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zeniplatin at doses ranging from 8 to 145 mg/m2, given as a 60- to 90-min i.v. infusion every 3 weeks
Study: 31448513
Drug: Palbociclib (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palbociclib (125 mg/d; 3 weeks on/1 week off) plus letrozole (2.5 mg/d, continuous)
Study: 31448513
Drug: Palbociclib (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palbociclib (125 mg/d; 3 weeks on/1 week off) plus fulvestrant (500 mg)
Study: 22784653
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) for 5 sessions every other day
Study: 15156249
Drug: Aescin +
Normalized name: escin
DrugBank: Escin (DB15907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aescin + essential phospholipids (AEPL) topical gel
Study: 9510100
Drug: Pulsed dye
Normalized name: amaranth dye
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed dye laser (PDL) treatment with fluences ranging from 3-6.5 J/cm2
Study: 2566879
Drug: Cetirizine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine (20 mg QD for 2 days)
Study: 27464582
Drug: S-1226 (4%,
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1226 (4%, 8%, or 12% CO2) administered by nebulization over a 2-minute period
Study: 27464582
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered by nebulization over a 2-minute period
Study: 23777653
Drug: High-frequency chest
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-frequency chest wall compression (HFCWC) therapy
Study: 21079179
Drug: Modafinil (100-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil (100-200 mg daily)
Study: 11978685
Drug: Biphasic insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Biphasic insulin lispro 25 (Mix25)
Study: 11689745
Drug: Aerobic training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerobic training (interval training, four times 4 min at 90‐95% of maximal heart rate, with a 3‐min jog in between, twice per week for 8 weeks)
Study: 7987090
Drug: Zidovudine prophylaxis
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zidovudine prophylaxis (oral from 14th gestational week and intravenous during delivery)
Study: 29722947
Drug: Nursing care
Normalized name: Petrolatum Topical application Ointment [NURSING CARE PROTECTIVE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nursing care intervention including knowledge, skills, diet, exercise, medication, and psychology through one-to-one consultation, individualized or group communication, establishing files, telephone follow-up, and WeChat guidance.
Study: 25846251
Drug: Integrated cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated cognitive-behavioral therapy (ICBT) plus standard care (SC)
Study: 18295436
Drug: Integrated cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated cognitive-behavioral therapy (ICBT)
Study: 19929251
Drug: Palonosetron in
Normalized name: palonosetron Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palonosetron in combination with dexamethasone
Study: 19929251
Drug: First generation
Normalized name: First generation cephalosporin
Approvals — FDA: no, EMA: no, PMDA: no
Description: First generation 5-HT3 receptor antagonists
Study: 10770746
Drug: Virosome vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virosome vaccine (0.5 ml on study day 0 or 0.25 ml on days 0 and 28)
Study: 10770746
Drug: Subunit vaccine
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subunit vaccine (0.5 ml on day 0 for older children and 0.25 ml on days 0 and 28 for younger children)
Study: 10770746
Drug: Virosome vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virosome vaccine
Study: 3539171
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg etretinate daily
Study: 20180695
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg of dried modified Saccharomyces cerevisiae oral fermentate (EpiCor)
Study: 15249749
Drug: Mistletoe treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mistletoe treatment
Study: 11522552
Drug: 1-3 cups
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-3 cups of coffee (175-525 mL/d) for 6 weeks
Study: 11522552
Drug: 4 cups
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 cups of coffee (700 mL/d) for 6 weeks
Study: 9296422
Drug: Isoproterenol (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoproterenol (all doses)
Study: 26897374
Drug: Pulsed Electric
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pulsed Electric Field (PEF) treatment at 15 kV/cm and 100 mL/min flow velocity
Study: 25052847
Drug: Melatonin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (10 mg) + Amitriptyline (25 mg)
Study: 17659464
Drug: HIIC (mitomycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIIC (mitomycin C 30 mg and cisplatin 100 mg in 2000 ml distilled water, heated to 42-45 degrees C, perfused for 30 min) and intravenous chemotherapy (5-FU 10-15 mg/kg, mitomycin C 0.1-0.15 mg/kg, adriamycin 0.5-1 mg/kg i.v drip, once a week for 2-3 weeks)
Study: 17659464
Drug: Intravenous chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous chemotherapy only (control group)
Study: 9236673
Drug: cA2 therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: cA2 therapy (1 mg/kg)
Study: 9236673
Drug: cA2 therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: cA2 therapy (10 mg/kg)
Study: 9236673
Drug: cA2 therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: cA2 therapy (1 mg/kg and 10 mg/kg)
Study: 9236673
Drug: cA2 therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: cA2 therapy
Study: 3531924
Drug: O‐(beta‐hydroxyethyl)‐rutosides (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: O‐(beta‐hydroxyethyl)‐rutosides (4 g/day orally)
Study: 28477684
Drug: UPDRS Activities
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UPDRS Activities of Daily Living (ADL) score
Study: 28477684
Drug: Dopamine agonist
Normalized name: Dopamine agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine agonist monotherapy
Study: 23444107
Drug: Concurrent task
Normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent task demands
Study: 18996868
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein supplement (40 g whey protein, 280 kcal, twice daily for 12 weeks)
Study: 18996868
Drug: Control supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control supplement (matched isocaloric supplement without added protein, twice daily for 12 weeks)
Study: 16842920
Drug: Antihistamine (olopatadine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihistamine (olopatadine hydrochloride)
Study: 12671528
Drug: Donepezil 5
Normalized name: donepezil 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil 5 mg daily in addition to perphenazine (8 mg/day or 16 mg/day)
Study: 12671528
Drug: Perphenazine (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perphenazine (8 mg/day or 16 mg/day)
Study: 1542491
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous 5-fluorouracil (5-FU) at a dose of 650 mg/m2 per day for 7 consecutive days, escalated in subsequent cycles
Study: 1542491
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous 5-fluorouracil (5-FU)
Study: 19814624
Drug: 7-valent pneumococcal
Normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-valent pneumococcal conjugate vaccine (7vPnC)
Study: 11284796
Drug: Specific immunotherapy
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific immunotherapy (SIT) with standardized extracts of house-dust mite for 3 years
Study: 9222184
Drug: Ketamine 0.10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 0.10 mg/kg/hr
Study: 9222184
Drug: Ketamine 0.40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 0.40 mg/kg/hr
Study: 9222184
Drug: Ketamine 0.60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 0.60 mg/kg/hr
Study: 7702801
Drug: Intravenous saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous saline load (2 L of 0.9% NaCl over 4 h)
Study: 7702801
Drug: Low-salt diet
Normalized name: Low-energy diets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-salt diet (20 mmol NaCl) with furosemide (3 x 40 mg, po)
Study: 3138220
Drug: Hyperthermia plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperthermia plus definitive radiotherapy (60 Gy delivered in 1.8‐2.0 Gy fractions 5 times/week with a boost of 5‐10 Gy through reduced portals to residual tumor; hyperthermia delivered twice weekly for 60 minutes at 43 degrees C)
Study: 29971593
Drug: Terlipressin (20-160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terlipressin (20-160 µg/h, maximum infusion rate of 4 mg/day)
Study: 29971593
Drug: Norepinephrine (4-30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine (4-30 µg/min)
Study: 25903799
Drug: TES program
Approvals — FDA: no, EMA: no, PMDA: no
Description: TES program for screening and treatment of psychological distress
Study: 20927506
Drug: Cryo/Cuff (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cryo/Cuff (3 × 10 min twice daily)
Study: 18214724
Drug: Cocaine medication
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine medication trials
Study: 16778696
Drug: Active conservative
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active conservative treatment (two regimens lasting 8 weeks)
Study: 14575968
Drug: Epoetin beta
Normalized name: Epoetin beta
DrugBank: Epoetin beta (DB19434)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Epoetin beta 300 IU/kg three times weekly
Study: 20358390
Drug: Topical SLS
Normalized name: vitamin B12
DrugBank: Cyanocobalamin Co-57 (DB09385)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical SLS 0.25%
Study: 20358390
Drug: Topical SLS
Normalized name: vitamin B12
DrugBank: Cyanocobalamin Co-57 (DB09385)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical SLS 0.5%
Study: 20358390
Drug: Topical SLS
Normalized name: vitamin B12
DrugBank: Cyanocobalamin Co-57 (DB09385)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical SLS 1%
Study: 20358390
Drug: Topical SLS
Normalized name: vitamin B12
DrugBank: Cyanocobalamin Co-57 (DB09385)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical SLS 2%
Study: 20358390
Drug: Topical capsaicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical capsaicin 1%
Study: 11347858
Drug: lacidipine 4
Normalized name: lacidipine 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: lacidipine 4 mg o.d. (increased to 6 mg if needed)
Study: 11347858
Drug: amlodipine 5
Normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: amlodipine 5 mg o.d. (increased to 10 mg if needed)
Study: 11347858
Drug: lacidipine 6
Normalized name: LACIDIPINE
DrugBank: Lacidipine (DB09236)
Approvals — FDA: no, EMA: no, PMDA: no
Description: lacidipine 6 mg (for patients requiring dose increase)
Study: 11347858
Drug: amlodipine 10
Normalized name: amlodipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: amlodipine 10 mg (for patients requiring dose increase)
Study: 8973988
Drug: 7-day 17
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day 17 beta-estradiol transdermal delivery system (TDS) applied to the abdomen
Study: 8973988
Drug: 7-day 17
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day 17 beta-estradiol transdermal delivery system (TDS) applied to the buttocks
Study: 1316059
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg lomefloxacin orally once daily (n = 259)
Study: 1316059
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg cefaclor every 8 hours (n = 263)
Study: 1316059
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg cefaclor
Study: 24912466
Drug: Ratings based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ratings based on entire therapy sessions
Study: 18246429
Drug: Second-generation antipsychotics
Normalized name: regenerated cellulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-generation antipsychotics (SGAs: olanzapine, quetiapine, risperidone, ziprasidone)
Study: 18246429
Drug: First-generation antipsychotic
Normalized name: benzethonium chloride / lidocaine hydrochloride Topical Gel [Tecnu First Aid]
Approvals — FDA: no, EMA: no, PMDA: no
Description: First-generation antipsychotic (FGA: perphenazine)
Study: 15766337
Drug: Fixed dose
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose regimen of diamorphine 0.4 mg in hyperbaric bupivacaine 0.5% 2.4 ml